Navigation Links
Lycera Initiates Phase 1 Clinical Trial of LYC-30937, a First-In-Class ATPase Modulator for Inflammatory Bowel Disease
Date:4/30/2015

NEW YORK and ANN ARBOR, Mich., April 30, 2015 /PRNewswire/ -- Lycera Corp., a biopharmaceutical company developing breakthrough immunomodulatory medicines to treat autoimmune diseases and cancer, today announced the initiation of a Phase 1 clinical trial of LYC-30937 in healthy volunteers.  LYC-30937 is an oral gut-directed ATPase modulator that is being studied for the treatment of inflammatory bowel disease (IBD).  LYC-30937 is designed to selectively induce cell death (apoptosis) in disease-causing immune cells, sparing normal cells. LYC-30937 was discovered and developed by Lycera based on technology licensed from the University of Michigan; the company maintains full worldwide development and commercial rights.

"The initiation of a clinical program for LYC-30937 marks a major milestone for Lycera.  This is our first program to enter the clinic, as well as the first ATPase modulator to commence clinical testing," said Paul Sekhri, President and CEO of Lycera Corp.  "Lycera is dedicated to advancing a portfolio of drugs based on breakthrough science that have the potential to offer substantial advances for patient treatment.  We are proud of the progress of our lead program, and look forward to further accelerating additional candidates in our pipeline."  In mid-2016, Lycera expects to initiate clinical studies for its lead immune-oncology product candidate, an agonist of RORgamma, as well as an anti-fibrotic agent, a highly selective ROCK2 (rho-associated kinase II) inhibitor.

"Inflammatory bowel diseases including ulcerative colitis and Crohn's disease, are chronic, life-long autoimmune diseases with significant medical needs and the potential for life-threatening complications," said Dr. H. Jeffrey Wilkins, Chief Medical Officer of Lycera.  "In contrast to current injectable treatments, LYC-30937 is an oral agent that acts on a novel target, locally in the gut.  Our development plan looks to demonstrate whether the promising preclinical data translates into an effective and well-tolerated novel treatment for patients with ulcerative colitis and inflammatory bowel disease.  We are excited to initiate the clinical program and anticipate the completion of the study by year end 2015."

About Lycera
Lycera is a biopharmaceutical company developing novel oral immune modulators for the treatment of autoimmune diseases and cancer. Based on successful progress of its world-class R&D platform, including expertise in immune metabolism, cell signaling, and immune cell differentiation, Lycera is commencing multiple clinical programs in 2015 and 2016. The company is advancing an oral, gut-directed ATPase modulator, designated LYC-30937, for the treatment of inflammatory bowel disease, which is currently in Phase 1 clinical testing, and oral RORgamma agonists for diverse applications in immune-oncology. In addition, Lycera has established two collaborations with Merck to discover, develop and commercialize small molecule therapies for autoimmune disorders. Lycera's leadership possesses deep experience in drug discovery, development, and commercialization and has established close relationships with renowned thought leaders and clinical researchers worldwide. Lead investors in Lycera include InterWest Partners, ARCH Venture Partners, Clarus Ventures, and EDF Ventures.

CONTACTS:

For Media:
Justin Jackson, Burns McClellan, on behalf of Lycera Corp.
212-213-0006, ext. 327
jjackson@burnsmc.com


'/>"/>
SOURCE Lycera Corp.
Copyright©2015 PR Newswire.
All rights reserved

Related medicine technology :

1. Lycera Announces Milestone in Merck Collaboration
2. Lycera to Present at the 2015 American Association for Cancer Research (AACR) Annual Meeting
3. Lycera Announces Research Showing Promising Anti-Cancer Activity of Novel, Oral Immunotherapy Candidates
4. Lycera Announces Presentation of Data on Anti-Tumor Activity of Novel Synthetic RORgamma Agonists at Society for Immunotherapy of Cancer Meeting
5. Benitec Biopharma Doses Fifth Patient And Initiates Additional Trial Site For Hepatitis C Trial
6. Debiopharm International SA Initiates Clinical Phase II Study Evaluating Debio 1450 in Staphylococcal Skin Infections
7. Bionomics Initiates Phase II Clinical Trial of BNC210 for Treatment of Anxiety
8. Edison Initiates Coverage on Tonix Pharmaceuticals
9. Rhythm Initiates Phase 2b Clinical Trial of Relamorelin for Diabetic Gastroparesis
10. Obalon Initiates U.S. Pivotal Trial of Novel Weight Loss Balloon
11. Edison Initiates Coverage on Threshold Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)...   Divoti USA will engrave and process ... of the latest FDA requirements, which stipulates new criteria regarding medical ... need of Medical ID jewelry such as Medical ID Bracelets, can ... in terms of the new FDA requirements . ... Divoti offers this dark mark fiber laser ...
(Date:10/11/2017)... 2017  BioPharmX Corporation (NYSE MKT: BPMX) researchers were ... innovative way to use nonlinear optical imaging to confirm ... drugs. A ... show how researchers from BioPharmX and the Wellman Center ... a suite of imaging techniques in what is called ...
(Date:10/11/2017)... , Oct. 11, 2017  True Health, a ... amplified its effort during National Breast Cancer Awareness ... cancer risks. ... Oncology calculated that more than 10 million American ... mutations in BRCA1 or BRCA2 and have not had ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Global Healthcare Management’s 4th Annual Kids ... Milford, NJ. This free event, sponsored by Global Healthcare Management’s CEO, Jon Letko, ... run is geared towards children of all ages; it is a non-competitive, non-timed event, ...
(Date:10/13/2017)... ... ... “The Journey: From the Mountains to the Mission Field”: the story of a ... “The Journey: From the Mountains to the Mission Field” is the creation of published ... all ages and currently teaches a class of ladies at her church, which she ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... Planet Fitness, ... the U.S., announced today its plans to open a flagship location in Covington, LA ... the former Rooms To Go store next to Office Depot in the Holiday Square ...
(Date:10/12/2017)... ... 12, 2017 , ... Asante, a nationally recognized health system ... their existing home health joint venture through an agreement, effective October 1, 2017, ... venture home health company with Asante, delivering clinically integrated care, for the past ...
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts at ... for the 49th Congress of the International Society of Paediatric Oncology (SIOP) ... Center for Cancer and Blood Disorders at Children’s National, and Stephen P. ...
Breaking Medicine News(10 mins):